Use of Export in Primary Percutaneous Coronary Intervention, In-Hospital and Short-term Outcomes and Optimal Time of Export
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Slow/No-reflow
Study Overview
Brief Summary
Aim of this single center randomized open label trial with blinded in-hospital outcomes assessment is designed with aim to compare manual thrombus aspiration followed by percutaneous coronary intervention (PCI) strategy with PCI alone.
Detailed Description
Clinical benefit of manual aspiration has been a contentious point of debate and it is Class III indication in current clinical practice guidelines, however, recent observational data by Kumar D et al. showed benefits of usage of export in terms of favorable in-hospital outcomes and lesser complication rate in patients with total occlusion, furthermore, benefits of usage of export was observed to be directly associated with duration of chest pain at the time of thrombus aspiration. However, these observations are limited to immediate and in-hospital outcomes and data regarding efficacy of manual thrombus aspiration are not available.
Hence this single center randomized open label trial is designed with specific aim to test the following hypothesis for STEMI patients with total occlusion undergoing primary PCI;
- Whether use of export catheter reduces in-hospital and short term adverse events
- Whether use of export reduces slow flow or no reflow
- Whether use of export reduces the use of intracoronary drugs
- Whether use of export within 6 hours of symptom onset significantly reduces in-hospital and short term adverse events
Consecutively recruited patients will be randomized to either primary PCI with export or primary PCI alone group in 2:1 ratio. Post aspiration immediate TIMI flow will be observed and all the patients will be observed for adverse outcomes (MACE) and complications including slow flow/no-reflow. Follow-up intervals will be at the end of one month of randomization and end of 6 month of randomization.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Masking Description
Blinded in-hospital outcomes assessment will be insured by separating patients recruitment and follow-up team and follow-up team will be kept blinded of randomization. All the patients will be assigned a unique identity code and collected data will be stored against the assigned code.
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients presenting with:-Symptoms of myocardial ischemia lasting for ≥30 minutes
- •Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads
- •Chest pain < 12 hours duration
- •Total occlusion (TIMI 0 flow)
- •Patients undergoing primary PCI
- •Informed consent
Exclusion Criteria
- •Patients with prior history of cardiac related surgery or intervention
- •Performance of a rescue PCI after thrombolysis
- •Known existence of a disease resulting in a life expectancy of less than 6 months
- •Killip class III, IV
Arms & Interventions
Intervention Group
Manual thrombus aspiration (use of export catheter) followed by primary PCI
Intervention: Export Catheter (Device)
Control group
Predilatation with balloon catheter (≤2.00 mm diameter) followed by primary PCI
Intervention: Balloon catheter (Device)
Outcomes
Primary Outcomes
Slow/No-reflow
Time Frame: Immediately after procedure
TIMI 0-II flow
Post thrombus aspiration TIMI flow
Time Frame: Immediately after export/balloon
Immediate TIMI flow after export/balloon
Major adverse cardiac events
Time Frame: In-hospital, at 1 month, and at 6 months
It will include All-cause death, Cardiovascular death, Re- infarction, Heart Failure, Cardiogenic shock, Cerebrovascular events, Bleeding events, and Stent thrombosis
Secondary Outcomes
No secondary outcomes reported
Investigators
Faiza Farooq
Acting Associate Professor
National Institute of Cardiovascular Diseases, Pakistan
